Recent News

• 03.31.2025 - ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
• 03.31.2025 - ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
• 03.24.2025 - ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
• 03.24.2025 - ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
• 03.13.2025 - ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
• 03.13.2025 - ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
• 03.11.2025 - ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
• 03.11.2025 - ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
• 02.25.2025 - ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
• 02.25.2025 - ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

Recent Filings

• 02.25.2025 - 8-K Current report
• 02.25.2025 - EX-99.1 EX-99.1
• 02.19.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.27.2025 - 8-K Current report
• 01.27.2025 - EX-99.1 EX-99.1